FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to immunology. Antibody to EphA4 and EphA4-binding fragment are presented. Also disclosed is a pharmaceutical composition, a nucleic acid, an expression vector, a host cell and a method of producing an antibody to the EphA4 and EphA4-binding fragment.
EFFECT: present invention can find further application in therapy of various conditions, particularly amyotrophic lateral sclerosis.
15 cl, 20 dwg, 8 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EphA4 ANTIBODY | 2020 |
|
RU2816371C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
